AbbVie Director Jennifer Davis Resigns From Board After Being Named Align Technology CEO
Jennifer L. Davis is stepping down from AbbVie's board after being named chief executive of Align Technology, the drugmaker said in an 8-K filed Monday.
Davis, a Class II director, notified AbbVie's board on Oct. 28 of her intent to resign, effective Nov. 2, 2026, in light of her recent appointment as CEO of Align Technology, Inc., according to the filing.
No dispute behind the exit
AbbVie said her resignation is not the result of any dispute or disagreement with the company on any matter relating to its operations, policies or practices. That wording is standard in director departure filings, and it ties the exit to her new job rather than to any conflict in the boardroom.
The resignation took effect Monday, the same day AbbVie made the disclosure.
What the filing does not say
AbbVie's board is split into classes, and Davis held a Class II seat. The 8-K does not name a successor, and it does not say whether AbbVie plans to fill the seat or shrink the size of the board.
The filing is limited to Item 5.02, which covers director and officer changes. It does not include any change to AbbVie's management team or its financial outlook.
For investors, the takeaway is straightforward: the move reflects a director taking on a chief executive role elsewhere, and AbbVie flagged no disagreement tied to her departure.
By the numbers
- Notice of resignation: Oct. 28, 2026
- Effective date: Nov. 2, 2026
- Board seat: Class II
Sources
- AbbVie Form 8-K on director resignation (Item 5.02), filed Nov. 2, 2026 (accession 0001104659-26-121322)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.